A new vaccine for osteosarcoma in dogs is being tested and has shown promising results. Dogs diagnosed with osteosarcoma currently face a grim prognosis. With aggressive surgical resection (amputation) and chemotherapy, survival times are generally around a year.
In contrast, dogs in the trial group with the new vaccine have lived up to 4 to 4 1/2 years. The vaccine is administered after surgical resection and chemotherapy. It is given as three doses, two weeks apart, then every 6 months.
Dr. Mason said: “These dogs live normal lives. They have an excellent quality of life. If you look at these dogs, other than the fact that they are missing a limb, you wouldn’t know anything’s wrong with them.
Photo: Dr. Nicola J. Mason, an associate professor of medicine at the University of Pennsylvania School of Veterinary Medicine, is studying a Listeria-based vaccine to treat dogs with osteosarcoma. (Courtesy of the University of Pennsylvania School of Veterinary Medicine)
The vaccine is not yet commercially available. Check out this article from the AVMA for more: